Cart
×
By investing in promising cutting-edge science, CureDuchenne has de-risked multiple investments, which have attracted biotech and pharmaceutical companies, as well as venture capital firms. With five successful exits since it was founded in 2003, CureDuchenne has been able to leverage over $1.5 billion from follow-on investments.